Monoclonal Antibody Combination Treatment With Casirivimab-Imdevimab Improves Symptoms, Daily Functioning, Overall HRQOL For Patients With COVID-19, Study Finds

Infectious Disease Advisor (8/12, Kuhns) reports, “Monoclonal antibody (mAb) combination treatment with casirivimab-imdevimab improves symptoms, daily functioning, and overall health-related quality of life (HRQOL) among patients with COVID-19 infection, according to study results.” The investigators used “several validated instruments” in order to “assess patient-reported health and well-being, including the Symptoms Evolution of COVID-19 (SE-C19); time to return to usual health; time to return to usual activities; the EuroQol 5 Dimension Level 5 (EQ-5D-5L) questionnaire; and the Work Productivity, Activity Impairment, and Classroom Impairment Questions (WPAI+CIQ):COVID-19 Infection questionnaire.” The findings were published in Infectious Diseases and Therapy.